An antibody against hemoglobin and use thereof

Abstract

The application discloses an anti-hemoglobin antibody and application thereof, and relates to the field of antibodies. The anti-hemoglobin antibody disclosed by the application comprises a heavy chain complementarity determining region and a light chain complementarity determining region, the antibody provides an important raw material source for detection of hemoglobin, and has good activity and sensitivity.

Description

[0001] Cross-references to related applications

[0002] This disclosure claims priority to Chinese Patent Application No. 202311164752.7, filed on September 8, 2023, entitled "An Antibody Against Hemoglobin and Its Application", the entire contents of which are incorporated herein by reference. Technical Field

[0003] This invention relates to the field of antibody technology, and more specifically, to an anti-hemoglobin antibody and its application. Background Technology

[0004] Hemoglobin (Hb) in feces, also known as fecal occult blood (FOB), is currently considered a tumor marker for rectal and colon cancer in clinical practice. Occult blood refers to bleeding in the gastrointestinal tract in amounts less than 5 ml / day, with no visible blood color to the naked eye and no visible destruction of red blood cells under a microscope. The fecal occult blood test is a routine diagnostic test for gastrointestinal bleeding, of great significance in the diagnosis of gastrointestinal diseases, and is also an important screening method for digestive tract tumors.

[0005] Clinical studies have confirmed that trace amounts of bleeding containing cancerous tumors in stool are the only detectable abnormality in early-stage colorectal cancer. Therefore, the fecal occult blood test has become a hot topic of ongoing research. Previously, chemical methods were used to detect fecal occult blood. In recent years, colloidal gold immunochromatography, an immunoassay using hemoglobin monoclonal antibodies, has been developed. Compared to traditional chemical methods, this method has significantly improved sensitivity and specificity, and is unaffected by diet or related medications, playing a crucial role in the diagnosis and treatment of early-stage colorectal cancer.

[0006] Fecal occult blood testing is a major diagnostic indicator for gastrointestinal bleeding and tumors. Currently, a commonly used screening method in clinical practice is a simple chemical test that utilizes heme (Hb), a major component of blood, which has a peroxidase-like effect. This type of method uses a variety of oxidizing colorimetric agents, such as benzidine, o-toluidine, o-toluidine, guaiac wood, reduced phenolphthalein, aminopyrrolidone, colorless malachite green, tetramethylbenzidine, diphenylamine, and dimethylbenzidine; therefore, there are numerous methods. While these methods are simple and easy to perform, they have low specificity and are susceptible to interference. Animal blood, meat, liver, foods rich in chlorophyll, iron supplements, vitamin C, and traditional Chinese medicine can all cause false positives.

[0007] Colloidal gold immunochromatography, based on immunological principles, offers significant advantages over the methods described above. It provides rapid diagnosis, is unaffected by interference from substances such as animal blood, exhibits better specificity, is simple to operate, requires no specialized equipment, and its primary raw material is an antibody targeting hemoglobin. Therefore, there is a strong demand in this field for high-performance anti-hemoglobin antibodies. Summary of the Invention

[0008] This application provides an anti-hemoglobin antibody, which provides an important source of raw materials for the detection of hemoglobin and has good activity and affinity.

[0009] To achieve the above objectives, according to one aspect of the present invention, an anti-hemoglobin antibody is provided, the antibody comprising three complementary determining regions having a heavy chain variable region having an amino acid sequence as shown in any one of SEQ ID NO:17, 18, 19 and three complementary determining regions having a light chain variable region having an amino acid sequence as shown in any one of SEQ ID NO:20, 21, 22.

[0010] To achieve the above objective, according to a second aspect of the present invention, an anti-hemoglobin antibody is provided, the antibody comprising the following complementarity-determining region:

[0011] HCDR1, which contains, or is composed of, the amino acid sequence shown in SEQ ID NO:1;

[0012] HCDR2, which contains, or is composed of, the amino acid sequence shown in SEQ ID NO:2;

[0013] HCDR3, which contains, or is composed of, the amino acid sequence shown in SEQ ID NO:3 or 29;

[0014] LCDR1, which contains, or is composed of, the amino acid sequence shown in SEQ ID NO:4;

[0015] LCDR2, which contains, or is composed of, the amino acid sequence shown in SEQ ID NO:5; and

[0016] LCDR3, which contains, or is composed of, the amino acid sequence shown in SEQ ID NO:6.

[0017] To achieve the above objectives, according to a third aspect of the present invention, an anti-hemoglobin antibody is provided, comprising a heavy chain variable region and / or a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in any one of SEQ ID NO: 17, 18, 19; and the amino acid sequence of the light chain variable region is shown in any one of SEQ ID NO: 20, 21, 22.

[0018] To achieve the above objectives, according to a fourth aspect of the present invention, an antihemoglobin antibody is provided, comprising a heavy chain and / or a light chain, wherein the amino acid sequence of the heavy chain is as shown in any one of SEQ ID NO: 23, 24, 25; and the amino acid sequence of the light chain is as shown in any one of SEQ ID NO: 26, 27, 28.

[0019] To achieve the above objectives, according to a fifth aspect of the present invention, an antibody conjugate is provided, the antibody conjugate comprising the antibodies described above.

[0020] To achieve the above objectives, according to a sixth aspect of the present invention, a reagent or kit is provided, the reagent or kit comprising the antibody or antibody conjugate described above.

[0021] To achieve the above objectives, according to a seventh aspect of the present invention, a method for detecting hemoglobin is provided, comprising: a) contacting the aforementioned antibody, antibody-drug conjugate, or reagent or kit with hemoglobin in a sample to be tested under conditions sufficient to induce an antibody / antigen binding reaction to form an immune complex; and b) detecting the presence of the immune complex, the presence of which indicates the presence of the antigen in the test sample.

[0022] To achieve the above objectives, according to an eighth aspect of the present invention, the use of the above-described antibody, antibody-drug conjugate, reagent, or kit in the preparation of a product for detecting hemoglobin is provided.

[0023] To achieve the above objectives, the present invention also provides a nucleic acid, a vector, a cell, and a method for preparing the above-mentioned antibody. Attached Figure Description

[0024] To more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly introduced below. It should be understood that the following drawings only show some embodiments of the present invention and should not be regarded as a limitation on the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort.

[0025] Figure 1 The results of SDS-PAGE for the reducing properties of Anti-Hb 17F10 Rmb1 to Anti-Hb 17F10 Rmb5 are shown. Detailed Implementation

[0026] In a first aspect, embodiments of the present invention provide an anti-hemoglobin antibody, the antibody comprising three complementary determining regions having a heavy chain variable region having an amino acid sequence as shown in any of SEQ ID NO:17, 18, 19 and three complementary determining regions having a light chain variable region having an amino acid sequence as shown in any of SEQ ID NO:20, 21, 22.

[0027] It should be noted that HCDR1, HCDR2, and HCDR3 are amino acid sequences identical to those of HCDR1, HCDR2, and HCDR3 in the same heavy chain variable region defined in the antibody described in the first aspect, and LCDR1, LCDR2, and LCDR3 are amino acid sequences identical to those of LCDR1, LCDR2, and LCDR3 in the same light chain variable region defined in the antibody described in the first aspect.

[0028] For example, HCDR1, HCDR2, and HCDR3 are amino acid sequences consistent with HCDR1, HCDR2, and HCDR3 of the heavy chain variable region shown in SEQ ID NO:17; LCDR1, LCDR2, and LCDR3 are amino acid sequences consistent with LCDR1, LCDR2, and LCDR3 of the light chain variable region shown in SEQ ID NO:20.

[0029] In this invention, the term "antibody" is used in the broadest sense and can include full-length monoclonal antibodies, bispecific or multispecific antibodies, chimeric antibodies, and antigen-binding fragments of antibodies, provided they exhibit the desired antigen-binding activity. An antigen-binding fragment of an antibody is a substance containing an antibody CDR that lacks some amino acids present in the full-length chain but can still specifically bind to an antigen. Such fragments are biologically active because they bind to the target antigen and can compete with other antigen-binding molecules (including intact antibodies) for binding to a given epitope. Examples of antigen-binding fragments of antibodies include, but are not limited to, Fab, Fab', F(ab')2, Fv fragments, disulfide-stabilized Fv fragments (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized bifunctional antibodies (ds diabody), single-chain antibody molecules (scFv), scFv dimers (bivalent bifunctional antibodies), and the smallest antibody recognition unit. The antigen-binding fragments of the aforementioned antibodies can bind to the same antigen as the parent antibody.

[0030] The antigen-binding fragments of the aforementioned antibodies typically possess the same binding specificity as the source antibody. Those skilled in the art will readily understand, based on the description of this invention, that the antigen-binding fragments of the aforementioned antibodies can be obtained, for example, by enzymatic digestion (including pepsin or papain) and / or by chemical reduction of disulfide bonds. Based on the complete antibody structure disclosed in this invention, those skilled in the art can readily obtain the aforementioned antigen-binding fragments.

[0031] The antigen-binding fragments of the aforementioned antibodies can also be obtained by recombinant genetic techniques known to those skilled in the art or by, for example, automated peptide synthesizers sold by AppliedBioSystems.

[0032] In this invention, the terms "complementarity-determining region," "CDR," or "CDRs" refer to highly variable regions of the heavy and light chains of immunoglobulins, specifically regions containing one or more, or even all, of the major amino acid residues that contribute to the binding of an antibody or antigen-binding fragment to the antigen or epitope it recognizes. In specific embodiments of this invention, CDRs refer to highly variable regions of the heavy and light chains of the antibody.

[0033] In this invention, the heavy chain complementarity determination region is represented by HCDR, which includes HCDR1, HCDR2 and HCDR3; the light chain complementarity determination region is represented by LCDR, which includes LCDR1, LCDR2 and LCDR3.

[0034] Methods for defining CDRs are well-known in the art and include: Kabat definition, Chothia definition, IMGT definition, Contact definition, and AbM definition. As described herein, "Kabat definition" refers to the definition system described in Kabat et al., USDept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). "Chothia definition" is found in Chothia et al., J Mol Biol 196:901-917 (1987). Other CDR definition methods may not strictly follow any of the above schemes but will still overlap at least partially with the CDR region defined by Kabat, although they may be shortened or lengthened based on predictions or experimental results of specific residues or residue groups. Exemplary defined CDRs are listed in Table 1 below; definitions vary slightly in different literature. Given the amino acid sequence of the variable region of an antibody, those skilled in the art can routinely determine which residues contain a specific CDR. It should be noted that CDRs defined by other methods, not limited to those in Table 1, are also within the scope of this disclosure.

[0035] Table 1: CDR Definition 1

[0036] CDR Kabat AbM2 IMGT Chothia HCDR1 <![CDATA[H31~H35 3 ]]> <![CDATA[H26~H35 3 ]]> <![CDATA[H26~H33..5 5 ]]> <![CDATA[H26~H32..34 4 ]]> HCDR2 H50~H65 H50~H58 H51~H57 H52~H56 HCDR3 H95~H102 H95~H102 H93~H102 H95~H102 LCDR1 L24~L34 L24~L34 L27~L32 L24~L34 LCDR2 L50~L56 L50~L56 L50~L51 L50~L56 LCDR3 L89~L97 L89~L97 L89~L97 L89~L97

[0037] 1 The CDRs defined in Table 1 are numbered according to the Kabat numbering system (see below), with amino acid numbers on the heavy chain represented by "H + number" and amino acid numbers on the light chain represented by "L + number". Those skilled in the art can readily map this Kabat numbering system to any variable region sequence without relying on any experimental data outside the sequence itself. As used herein, "Kabat numbering" refers to the numbering system described by Kabat et al., USD ept. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983).

[0038] 2 As used in Table 1, “AbM” with a lowercase “b” refers to the CDR defined by the “AbM” antibody modeling software of Oxford Molecular.

[0039] 3 If neither H35A nor H35B exists, then HCDR1 ends at bit 35; if only H35A exists, then HCDR1 ends at bit 35A; if both H35A and H35B exist, then HCDR1 ends at bit 35B.

[0040] 4 If neither H35A nor H35B exists, then HCDR1 ends at bit 32; if only H35A exists, then HCDR1 ends at bit 33; if both H35A and H35B exist, then HCDR1 ends at bit 34.

[0041] 5 If neither H35A nor H35B exists, then HCDR1 ends at bit 33; if only H35A exists, then HCDR1 ends at bit 34; if both H35A and H35B exist, then HCDR1 ends at bit 35.

[0042] According to embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 is defined by any one or a combination of systems such as Kabat, Chothia, IMGT, AbM or Contact.

[0043] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the Kabat system.

[0044] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the Chothia system.

[0045] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the IMGT system.

[0046] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the AbM system.

[0047] In some optional embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by the Contact system.

[0048] In some alternative embodiments of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are defined by a combination of Kabat, Chothia, IMGT, AbM, or Contact systems.

[0049] According to embodiments of the present invention, the Kabat numbering positions corresponding to the amino acid sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, or LCDR3 defined by the Kabat, Chothia, AbM, or IMGT systems are as follows:

[0050] CDR Kabat AbM IMGT Chothia HCDR1 H31~H35 H26~H35 H26~H33 H26~H32 HCDR2 H50~H65 H50~H58 H51~H57 H52~H56 HCDR3 H95~H102 H95~H102 H93~H102 H95~H102 LCDR1 L24~L34 L24~L34 L27~L32 L24~L34 LCDR2 L50~L56 L50~L56 L50~L51 L50~L56 LCDR3 L89~L97 L89~L97 L89~L97 L89~L97

[0051] Secondly, embodiments of the present invention provide an antibody against hemoglobin, the antibody comprising the following complementarity-determining regions:

[0052] HCDR1, which contains, or is composed of, the amino acid sequence shown in SEQ ID NO:1;

[0053] HCDR2, which contains, or is composed of, the amino acid sequence shown in SEQ ID NO:2;

[0054] HCDR3, which contains, or is composed of, the amino acid sequence shown in SEQ ID NO:3 or 29;

[0055] LCDR1, which contains, or is composed of, the amino acid sequence shown in SEQ ID NO:4;

[0056] LCDR2, which contains, or is composed of, the amino acid sequence shown in SEQ ID NO:5; and

[0057] LCDR3, which contains, or is composed of, the amino acid sequence shown in SEQ ID NO:6.

[0058] According to an embodiment of the present invention, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 is defined by the Kabat system.

[0059] In this invention, the "frame region" or "FR" region includes the heavy chain frame region and the light chain frame region, referring to the regions in the antibody heavy chain variable region and light chain variable region other than the CDR; wherein, the heavy chain frame region can be further subdivided into adjacent regions separated by the CDR, including the HFR1, HFR2, HFR3 and HFR4 frame regions; the light chain frame region can be further subdivided into adjacent regions separated by the CDR, including the LFR1, LFR2, LFR3 and LFR4 frame regions.

[0060] In this invention, the heavy chain variable region is obtained by connecting the following numbered CDRs and FRs in the following combination: HFR1-HCDR1-HFR2-HCDR2-HFR3-HCDR3-HFR4; the light chain variable region is obtained by connecting the following numbered CDRs and FRs in the following combination: LFR1-LCDR1-LFR2-LCDR2-LFR3-LCDR3-LFR4.

[0061] In an optional embodiment, the antibody described in the first or second aspect further comprises at least one of HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3, and LFR4;

[0062] The HFR1 includes / is such as SEQ ID NO:7 or an amino acid sequence having at least 80% identity with it;

[0063] The HFR2 includes / is such as SEQ ID NO:8 or an amino acid sequence having at least 80% identity with it;

[0064] The HFR3 includes / is, for example, SEQ ID NO:9 or an amino acid sequence having at least 80% identity with it;

[0065] The HFR4 includes / is, for example, SEQ ID NO:10 or an amino acid sequence having at least 80% identity with it;

[0066] The LFR1 includes / such as SEQ ID NO:11 or an amino acid sequence having at least 80% identity with it;

[0067] The LFR2 includes / is, for example, SEQ ID NO:12 or an amino acid sequence having at least 80% identity with it;

[0068] The LFR3 includes / is, for example, SEQ ID NO:13 or an amino acid sequence having at least 80% identity with it;

[0069] The LFR4 includes / such as SEQ ID NO:14 or an amino acid sequence having at least 80% identity with it.

[0070] It should be noted that, in other embodiments, the amino acid sequences of each frame region of the anti-hemoglobin antibody provided by the present invention may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the corresponding frame regions (SEQ ID NO: 7, 8, 9, 10, 11, 12, 13, or 14) mentioned above.

[0071] In an optional embodiment, the HFR2 includes / as shown in SEQ ID NO:30, an amino acid sequence.

[0072] In an optional embodiment, the LFR1 includes / as shown in SEQ ID NO:31, an amino acid sequence.

[0073] In an optional embodiment, the LFR3 includes / as shown in SEQ ID NO:32, an amino acid sequence.

[0074] Thirdly, embodiments of the present invention provide an anti-hemoglobin antibody comprising a heavy chain variable region and / or a light chain variable region, wherein the amino acid sequence of the heavy chain variable region is shown in any one of SEQ ID NO: 17, 18, 19, and the amino acid sequence of the light chain variable region is shown in any one of SEQ ID NO: 20, 21, 22.

[0075] In an optional implementation, the heavy chain variable region and the light chain variable region described in the first or third aspect above are selected from any combination of the following:

[0076] combination VH VL 1 SEQ ID NO:17 SEQ ID NO:20 2 SEQ ID NO:18 SEQ ID NO:20 3 SEQ ID NO:19 SEQ ID NO:20 4 SEQ ID NO:18 SEQ ID NO:21 5 SEQ ID NO:18 SEQ ID NO:22

[0077] In optional embodiments, the antibodies described in the first, second, and third aspects above further include a constant region.

[0078] In an optional implementation, the constant region includes a heavy chain constant region and / or a light chain constant region.

[0079] In an optional implementation, the heavy chain constant region is selected from any one of the heavy chain constant regions of IgG, IgA, IgM, IgE, and IgD, or a combination of multiple constant region segments.

[0080] In an optional embodiment, the heavy chain constant region includes CH1 of IgG, the hinge region of IgG, CH2 of IgM, CH3 of IgM, and / or CH4 of IgM.

[0081] In an optional implementation, the IgG is selected from IgG1, IgG2, IgG3 or IgG4.

[0082] In an optional implementation, the light chain constant region is selected from the κ-type or λ-type light chain constant region.

[0083] In an optional implementation, the species source of the constant region is cattle, horses, dairy cows, pigs, sheep, rats, mice, dogs, cats, rabbits, donkeys, deer, mink, chickens, ducks, geese, turkeys, fighting cocks, or humans.

[0084] In an optional implementation, the species source of the constant region is mice.

[0085] In an optional embodiment, the heavy chain constant region sequence (CH) is as shown in SEQ ID NO:15, and the light chain constant region sequence (CL) is as shown in SEQ ID NO:16.

[0086] It should be noted that, in other embodiments, the constant region sequence may have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the aforementioned constant region (SEQ ID NO: 15 or 16).

[0087] Fourthly, the present invention provides an antihemoglobin antibody comprising a heavy chain and / or a light chain, wherein the amino acid sequence of the heavy chain is as shown in any one of SEQ ID NO:23, 24, 25, and the amino acid sequence of the light chain is as shown in any one of SEQ ID NO:26, 27, 28.

[0088] In an optional embodiment, the antibody described in the first, second, third, or fourth aspect above includes any combination of the heavy and light chains:

[0089] combination H L 1 SEQ ID NO:23 SEQ ID NO:26 2 SEQ ID NO:24 SEQ ID NO:26 3 SEQ ID NO:25 SEQ ID NO:26 4 SEQ ID NO:24 SEQ ID NO:27 5 SEQ ID NO:24 SEQ ID NO:28

[0090] Fifthly, the present invention provides an antibody conjugate comprising the antibodies described above.

[0091] In an optional embodiment, the antibody conjugate further includes biotin or a biotin derivative conjugated with the antibody.

[0092] In an optional embodiment, the antibody conjugate further includes a marker conjugated to the antibody.

[0093] In an optional implementation, the aforementioned marker refers to a type of substance that has properties such as luminescence, color development, and radioactivity that can be directly observed by the naked eye or detected or probed by instruments. Through these properties, qualitative or quantitative detection of the corresponding target can be achieved.

[0094] In optional embodiments, the markers include, but are not limited to, fluorescent dyes, enzymes, radioisotopes, chemiluminescent reagents, and nanoparticle markers.

[0095] In practical use, those skilled in the art can select appropriate markers according to the detection conditions or actual needs. Regardless of the marker used, it falls within the protection scope of this invention.

[0096] In optional embodiments, the fluorescent dyes include, but are not limited to, fluorescein dyes and their derivatives (e.g., including but not limited to fluorescein isothiocyanate (FITC), hydroxyfluorescein (FAM), tetrachlorofluorescein (TET), etc., or their analogues), rhodamine dyes and their derivatives (e.g., including but not limited to red rhodamine (RBITC), tetramethylrhodamine (TAMRA), rhodamine B (TRITC), etc., or their analogues), and Cy series dyes and their derivatives (e.g., including but not limited to Cy2, Cy3, Cy3B, Cy3.5, C...). y5, Cy5.5, Cy3 and other similar substances), Alexa series dyes and their derivatives (including but not limited to Alexa Fluor 350, 405, 430, 488, 532, 546, 555, 568, 594, 610, 33, 647, 680, 700, 750 and other similar substances) and protein dyes and their derivatives (including but not limited to phycoerythrin (PE), phycocyanin (PC), allophycocyanin (APC), polydiophytoxanthin-chlorophyll protein (preCP) and other similar substances).

[0097] In optional embodiments, the enzymes include, but are not limited to, horseradish peroxidase, alkaline phosphatase, β-galactosidase, glucose oxidase, carbonic anhydrase, acetylcholinesterase, and glucose-6-phosphate dehydrogenase.

[0098] In optional embodiments, the radioactive isotopes include, but are not limited to, 212Bi, 131I, 111In, 90Y, 186Re, 211At, 125I, 188Re, 153Sm, 213Bi, 32P, 94mTc, 99mTc, 203Pb, 67Ga, 68Ga, 43Sc, 47Sc, 110mIn, 97Ru, 62Cu, 64Cu, 67Cu, 68Cu, 86Y, 88Y, 121Sn, 161Tb, 166Ho, 105Rh, 177Lu, 172Lu, and 18F.

[0099] In optional embodiments, the chemiluminescent reagents include, but are not limited to, luminol and its derivatives, luciferin, fluorescein and its derivatives, ruthenium bipyridine and its derivatives, acridine ester and its derivatives, dioxane and its derivatives, rofenine and its derivatives, and peroxazone and its derivatives.

[0100] In optional embodiments, the nanoparticle-based markers include, but are not limited to, nanoparticles, colloids, organic nanoparticles, magnetic nanoparticles, quantum dot nanoparticles, and rare earth complex nanoparticles.

[0101] In optional embodiments, the colloid includes, but is not limited to, colloidal metals, dispersed dyes, dye-labeled microspheres, and latexes.

[0102] In optional embodiments, the colloidal metal includes, but is not limited to, colloidal gold, colloidal silver, and colloidal selenium.

[0103] In an optional embodiment, the colloidal metal is colloidal gold.

[0104] In an optional embodiment, the antibody conjugate further includes a solid-phase carrier conjugated to the antibody.

[0105] In an optional embodiment, the solid support is selected from microspheres, plates, and membranes.

[0106] In optional embodiments, the solid support includes, but is not limited to, magnetic microspheres, plastic microspheres, plastic microparticles, microporous plates, glass, capillaries, nylon, and nitrocellulose membranes.

[0107] In a sixth aspect, the present invention provides a reagent or kit comprising the antibody or antibody conjugate described above.

[0108] As previously mentioned, the antibodies in some embodiments or examples of this invention can effectively bind to hemoglobin. Therefore, reagents or kits containing the hemoglobin antibodies can effectively perform qualitative or quantitative detection of hemoglobin. The reagents or kits provided by this invention can be used, for example, for detections involving the specific binding properties of hemoglobin and its antibodies, such as immunoblotting and immunoprecipitation. As previously mentioned, the antibodies in some embodiments or examples of this invention have higher binding activity or affinity to hemoglobin; therefore, reagents or kits containing the antibodies have higher detection sensitivity or specificity.

[0109] In a seventh aspect, the present invention provides a method for detecting hemoglobin, comprising: a) contacting the antibody, antibody-conjugate, reagent or kit described above with hemoglobin in a sample to be tested under conditions sufficient to cause an antibody / antigen binding reaction to form an immune complex; and b) detecting the presence of the immune complex, the presence of the complex indicating the presence of the antigen in the test sample;

[0110] In an optional embodiment, the immune complex further includes a second antibody that binds to the antibody.

[0111] In an optional embodiment, the immune complex further includes a second antibody that binds to hemoglobin.

[0112] Eighthly, the present invention provides the use of the above-described antihemoglobin antibody, antibody conjugate, or the above-described reagent or kit in the preparation of products for detecting hemoglobin.

[0113] Ninthly, the present invention provides a nucleic acid molecule encoding the above-mentioned antibody.

[0114] In a tenth aspect, the present invention provides a carrier containing the above-mentioned nucleic acid molecules.

[0115] In the eleventh aspect, the present invention provides cells containing the above-described carrier.

[0116] In a twelfth aspect, the present invention provides a method for preparing antihemoglobin antibodies, comprising: culturing cells as described above.

[0117] Based on the amino acid sequence of the antihemoglobin antibody disclosed in this invention, those skilled in the art will readily conceive of preparing the antihemoglobin antibody using genetic engineering or other techniques (chemical synthesis, recombinant expression), such as isolating and purifying the antibody from the culture product of recombinant cells capable of recombinantly expressing the antibody described in any of the preceding claims. This is easily achievable by those skilled in the art. Therefore, regardless of the technique used to prepare the antihemoglobin antibody of this invention, it falls within the protection scope of this invention.

[0118] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all conventional products that can be purchased commercially.

[0119] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. While any methods and materials similar to or equivalent to those described herein may be used in the practice or testing of formulations or unit doses herein, some methods and materials are described hereby. Unless otherwise stated, the techniques employed or considered herein are standard methods. Materials, methods, and examples are illustrative and not limiting in nature.

[0120] Unless otherwise specified, the practice of this invention will employ conventional techniques of cell biology, molecular biology (including recombinant technologies), microbiology, biochemistry, and immunology, which are within the capabilities of those skilled in the art. This technique is well explained in the literature, such as *Molecular Cloning: A Laboratory Manual*, 2nd edition (Sambrook et al., 1989); *Oligonucleotide Synthesis* (edited by M.J. Gait, 1984); *Animal Cell Culture* (edited by R.R. Freshney, 1987); *Methods in Enzymology* (Academic Press, Inc.); *Handbook of Experimental Immunology* (edited by D.M. Weir and C.C. Blackwell); *Gene Transfer Vectors for Mammalian Cells* (edited by J.M. Miller and M.P. Calos, 1987); *Current Protocols in Molecular Biology* (edited by F.M. Mausubel et al., 1987); and *PCR: The Polymerase Chain Reaction*. The references cited in the references are: "Reaction" (Mullis et al., ed., 1994); and "Current Protocols in Immunology" (JEColigan et al., ed., 1991), each of which is explicitly incorporated herein by reference.

[0121] The features and performance of the present invention will be further described in detail below with reference to embodiments.

[0122] Example 1: Preparation of Anti-Hb 17F10 Monoclonal Antibody

[0123] In this embodiment, restriction endonucleases and Prime Star DNA polymerase were purchased from Takara. The MagExtractor RNA extraction kit was purchased from TOYOBO. BD SMART TMThe RACE cDNA Amplification Kit was purchased from Takara. The pMD-18T vector was purchased from Takara. The plasmid extraction kit was purchased from Tiangen Pharmaceuticals. Primer synthesis and gene sequencing were performed by Invitrogen. The hybridoma cell line secreting the Anti-Hb 17F10 monoclonal antibody was a hybridoma cell line prepared in our laboratory and was revived for later use.

[0124] (1) Antibody gene preparation

[0125] mRNA was extracted from hybridoma cell lines secreting Anti-Hb 17F10 monoclonal antibody, and DNA products were obtained by RT-PCR. The product was then inserted into the pMD-18T vector after an A-addition reaction with rTaq DNA polymerase. The vector was then transformed into DH5α competent cells. After bacterial growth, four clones of the Heavy Chain and Light Chain genes were collected and sent to a gene sequencing company for sequencing.

[0126] (2) Sequence analysis of the variable region gene of Anti-Hb 17F10 antibody

[0127] The gene sequences obtained from the sequencing were analyzed in the Kabat antibody database and VNTI11.5 software was used to confirm that the genes amplified by both heavy and light chain primer pairs were correct. Among the gene fragments amplified by the Light Chain primer pair, the VL gene sequence was 318 bp, with a 57 bp leader peptide sequence preceding it; among the gene fragments amplified by the Heavy Chain primer pair, the VH gene sequence was 348 bp, belonging to the VH1 gene family, with a 57 bp leader peptide sequence preceding it.

[0128] (3) Construction of recombinant antibody expression plasmid

[0129] pcDNA TM 3.4 The vector is a constructed recombinant antibody eukaryotic expression vector. This expression vector has been introduced with multiple cloning restriction sites such as HindIII, BamHI, and EcoRI, and is named pcDNA3.4A expression vector, hereinafter referred to as 3.4A expression vector. Based on the sequencing results of the variable region gene of the antibody in pMD-18T, VL and VH gene-specific primers of this antibody were designed, with HindIII and EcoRI restriction sites and protective bases at both ends, respectively. The 0.70kb Light Chain gene fragment and the 1.38kb Heavy Chain gene fragment were amplified by PCR.

[0130] The Heavy Chain and Light Chain gene fragments were digested with HindIII / EcoRI, and the 3.4A vector was also digested with HindIII / EcoRI. After purification and recovery of the fragments and vector, the Heavy Chain gene and Light Chain gene were ligated into the 3.4A expression vector to obtain recombinant expression plasmids of Heavy Chain and Light Chain, respectively.

[0131] 2. Recombinant antibody production

[0132] HEK293 cells were revived early and passaged to a 200ml volume to achieve a cell density of 3–5 × 10⁻⁶ cells / mL. 6 Cell density reached the required antibody concentration and cell viability >95%; cells were washed by centrifugation, reconstituted with culture medium, and the cell density was adjusted to 2.9 × 10⁻⁶ cells / ml. 6 Cells were washed at a concentration of cells / ml and reconstituted with culture medium, which served as a cell dilution buffer. Plasmid DNA and transfection reagent dilution buffers were prepared separately using culture medium. The transfection reagent dilution buffer was added to the plasmid DNA dilution buffer, mixed well, and incubated at room temperature for 15 min. This mixture was then slowly added to the cell dilution buffer over 1 min, mixed well, and samples were taken for cell counting. Cell viability after transfection was recorded and observed. The cells were then incubated at 35°C with a rotation speed of 120 rpm and a CO2 concentration of 8%. After 13 days, the samples were centrifuged and collected. The supernatant was purified using a protein A affinity chromatography column. 6 μg of the purified antibody was subjected to reducing SDS-PAGE, as shown in the figure. The reducing SDS-PAGE showed two bands: one with a Mr of 50 kDa (heavy chain) and the other with a Mr of 28 kDa (light chain).

[0133] The resulting antibody was named Anti-Hb 17F10Rmb1. Mutations were performed on Anti-Hb 17F10Rmb1 to obtain a mutant antibody. The heavy chain (H) and light chain (L) sequences of the above antibody are shown in the table below:

[0134] Table 2: Antibody Sequences

[0135]

[0136]

[0137] Example 2: Antibody Performance Detection

[0138] 1. Activity identification

[0139] Dilute human hemoglobin (from Feipeng Biotechnology) with coating buffer (main component NaHCO3) to 3ug / ml, 100uL per well, overnight at 4℃; the next day, wash twice with washing buffer (main component Na2HPO4 + NaCl), pat dry; add blocking buffer (20% BSA + 80% PBS), 120uL per well, incubate at 37℃ for 1h, pat dry; add diluted purified antibody and control antibody, 100uL / well, incubate at 37℃ for 30min; wash 5 times with washing buffer, pat dry; add goat anti-mouse IgG-HRP, 100uL per well, incubate at 37℃ for 30min; wash 5 times with washing buffer, pat dry; add chromogenic solution A (50uL / well), add chromogenic solution B (50uL / well), incubate for 10min; add stop solution, 50uL / well; read OD value at 450nm (reference 630nm) on the microplate reader.

[0140] Notes: Solution A (main components: citric acid + sodium acetate + acetanilide + urea peroxide); Solution B (main components: citric acid + EDTA·2Na + TMB + concentrated HCl); Stop solution (EDTA·2Na + concentrated H2SO4)

[0141] Table 3: Activity Data

[0142] Concentration (ng / ml) 125 62.5 31.25 15.625 7.8125 0 Comparison 0.921 0.563 0.309 0.196 0.082 0.017 Anti-Hb 17F10Rmb1 1.561 0.882 0.463 0.239 0.108 0.061 Anti-Hb 17F10Rmb2 2.058 1.402 0.715 0.336 0.179 0.084 Anti-Hb 17F10Rmb3 1.894 1.153 0.638 0.325 0.168 0.097 Anti-Hb 17F10Rmb4 2.228 1.666 0.931 0.487 0.315 0.056 Anti-Hb 17F10Rmb5 2.332 2.206 1.872 1.127 0.573 0.095

[0143] 2. Stability assessment

[0144] The above-mentioned antibodies were placed at 4℃ (refrigerator), -80℃ (refrigerator), and 37℃ (incubator) for 21 days. Samples were taken at 7, 14, and 21 days for observation of their state, and the activity of the 21-day sample was tested. The results showed that no significant changes in protein state were observed under the three testing conditions after 21 days, and the activity did not decrease with increasing testing temperature, indicating that the above-mentioned antibodies were stable. Table 4 below shows the OD results of enzyme immunoassay for antibody Anti-Hb 17F10Rmb3 after 21 days of testing.

[0145] Table 4: Stability Data

[0146] Sample concentration (ng / ml) 125 31.25 0 4℃, 21-day sample 1.949 0.619 0.058 -80℃, 21-day sample 1.965 0.644 0.046 37℃, 21-day sample 1.993 0.635 0.049

[0147] 3. Performance testing of colloidal gold platform

[0148] 3.1 Antibody labeling process

[0149] (1) Adjust the pH of the label: Take 10 ml of 40,000 colloidal gold, centrifuge, add 150 μl of 0.2 M K2CO3, and stir to mix for 2 min;

[0150] (2) Antibody conjugation: Add 200ug of Anti-Hb (from Feipeng Biotechnology) to each antibody and stir for 15min;

[0151] (3) Sealing: Add 10% (by mass volume) BSA and stir for 15 min;

[0152] (4) Centrifugation and storage: 10000 rpm / 7 min / room temperature, remove supernatant, resuspend in gold standard reconstitution solution to 1 ml, and store at 4℃ for later use;

[0153] 3.2 Wrapping

[0154] (1) Assemble the nitrocellulose membrane and colloidal gold PVC base plate for later use;

[0155] (2) Dilute the antibodies Anti-Hb 17F10Rmb1, Anti-Hb 17F10Rmb2, Anti-Hb 17F10Rmb3, Anti-Hb 17F10Rmb4, Anti-Hb 17F10Rmb5, and the control antibody (from Feipeng Biotechnology) to 1.0-2.0 mg / ml. Use a gold sputtering membrane spectrometer to evenly draw lines on the NC membrane, then place it in a 50℃ incubator for drying for at least 4 hours. Assemble, cut strips, and add samples for detection.

[0156] 3.3 Detection

[0157] (1) Samples: human hemoglobin control samples of different concentrations

[0158] (2) Detection method: Colloidal gold detection. The intensity of the test line is observed visually to determine the result. The intensity of the displayed band color indicates the activity of antigen-antibody binding in the sample. The color of the T line of the colloidal gold test strip is compared with the standard color card. The closest color is selected, and the corresponding color number is used to indicate the activity of the product. The smaller the number, the stronger the color and the higher the activity; the larger the number, the weaker the color and the lower the activity. A "+" after the number indicates slightly stronger, a "-" after the number indicates slightly weaker, and "B" represents negative. The results are shown in Table 5. The results show that on the colloidal gold platform, the detection sensitivity of Anti-Hb 17F10Rmb1, Anti-Hb17F10Rmb2, Anti-Hb 17F10Rmb3, Anti-Hb 17F10Rmb4, and Anti-Hb 17F10Rmb5 is better than that of the control antibody.

[0159] Table 5: Colloidal Gold Detection Data

[0160]

[0161] The partial amino acid sequences involved in this application are shown in Table 6:

[0162] Table 6: Amino Acid Sequence List

[0163]

[0164]

[0165]

[0166] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the present invention by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. An antibody against hemoglobin, wherein the complementarity-determining region of the antibody comprises: three complementarity-determining regions of a heavy chain variable region as shown in any one of SEQ ID NO: 17, 18, 19, and three complementarity-determining regions of a light chain variable region as shown in any one of SEQ ID NO: 20, 21, 22, wherein the complementarity-determining regions of the variable region are defined by any one of the Kabat, Chothia, IMGT, AbM, or Contact systems.

2. An antibody against hemoglobin, characterized in that, The antibody includes the following complementarity-determining regions: HCDR1, whose amino acid sequence is shown in SEQ ID NO:1; HCDR2, the amino acid sequence of which is shown in SEQ ID NO:2; HCDR3, whose amino acid sequence is shown in SEQ ID NO:3 or 29; LCDR1, whose amino acid sequence is shown in SEQ ID NO:4; LCDR2, whose amino acid sequence is shown in SEQ ID NO:5; and LCDR3, whose amino acid sequence is shown in SEQ ID NO:

6.

3. The antibody according to claim 1 or 2, characterized in that, The antibody also contains HFR1, HFR2, HFR3, HFR4, LFR1, LFR2, LFR3, and LFR4.

4. The antibody according to claim 3, characterized in that, The amino acid sequence of HFR1 has at least 80% identity with SEQ ID NO:7; The amino acid sequence of HFR2 has at least 80% identity with SEQ ID NO:8; The amino acid sequence of HFR3 has at least 80% identity with SEQ ID NO:9; The amino acid sequence of the HFR4 has at least 80% identity with SEQ ID NO:10; The amino acid sequence of LFR1 has at least 80% identity with SEQ ID NO:11; The amino acid sequence of LFR2 has at least 80% identity with SEQ ID NO:12; The amino acid sequence of LFR3 has at least 80% identity with SEQ ID NO:13; The amino acid sequence of the LFR4 has at least 80% identity with SEQ ID NO:

14.

5. An antibody against hemoglobin, comprising a heavy chain variable region and a light chain variable region, characterized in that, The combination of the heavy chain variable region and the light chain variable region is selected from any of the following combinations: 。 6. The antibody according to any one of claims 1, 2, 4, and 5, characterized in that, The antibody also contains a constant region.

7. The antibody according to claim 6, characterized in that, The constant region includes the heavy chain constant region and / or the light chain constant region.

8. The antibody according to claim 7, characterized in that, The heavy chain constant region is selected from any one of the heavy chain constant regions of IgG, IgA, IgM, IgE, and IgD, or a combination of multiple constant region segments.

9. The antibody according to claim 7, characterized in that, The heavy chain constant region includes CH1 of IgG, the hinge region of IgG, CH2 of IgM, CH3 of IgM, and / or CH4 of IgM.

10. The antibody according to claim 6, characterized in that, The species source of the constant region is cattle, horses, pigs, sheep, goats, rats, mice, dogs, cats, rabbits, donkeys, deer, mink, chickens, ducks, geese, or humans.

11. The antibody according to claim 6, characterized in that, The species source of the constant region is mice.

12. The antibody according to claim 7, characterized in that, The amino acid sequence of the heavy chain constant region has at least 80% identity with SEQ ID NO:

15.

13. The antibody according to claim 7, characterized in that, The amino acid sequence of the light chain constant region has at least 80% identity with SEQ ID NO:

16.

14. An antibody against hemoglobin, comprising a heavy chain and a light chain, characterized in that, The heavy chain and the light chain are selected from any combination of the following: 。 15. An antibody conjugate, characterized in that, The antibody-drug conjugate includes the antibody as described in any one of claims 1 to 14 and biotin, a label, or a solid-phase carrier conjugated to the antibody.

16. The antibody according to claim 15, characterized in that, The markers are selected from fluorescent dyes, enzymes, radioactive isotopes, chemiluminescent reagents, and nanoparticle markers.

17. A reagent or kit, characterized in that, The reagent or kit comprises the antibody as described in any one of claims 1 to 14 or the antibody conjugate as described in claim 15 or 16.

18. Use of the antibody according to any one of claims 1 to 14, the antibody conjugate according to claim 15 or 16, or the reagent or kit according to claim 17 in the preparation of a product for detecting hemoglobin.

19. The use according to claim 18, characterized in that, include: a) Under conditions sufficient to allow an antibody / antigen binding reaction to occur, the antibody of any one of claims 1 to 14, the antibody conjugate of claim 15 or 16, or the reagent or kit of claim 17 is brought into contact with hemoglobin in the sample to be tested to form an immune complex. and b) Detect the presence of the immune complex, the presence of which indicates the presence of the antigen in the sample to be tested.

20. The use according to claim 19, characterized in that, The immune complex further includes a second antibody, which binds to the antibody.

21. The use according to claim 19, characterized in that, The immune complex also includes a second antibody that binds to hemoglobin.

22. A nucleic acid, characterized in that, The nucleic acid encodes the antibody according to any one of claims 1 to 14.

23. A carrier, characterized in that, The vector contains the nucleic acid as described in claim 22.

24. A cell characterized by, The cell contains the nucleic acid of claim 22 or the vector of claim 23.

25. A method for preparing the antibody according to any one of claims 1 to 14, characterized in that, The method comprises: culturing the cells of claim 24.

Images